Australia's Race Oncology rises after S.Korea approves tumor drug for clinical trials

Racura Oncology

24/09/2025 03:57

** Shares of Australia's Race Oncology RAC.AX rise as much as 13% to A$3.39 after a two-day slide

** Biopharmaceutical co says South Korea has approved its investigational new drug application for Phase 1 clinical trial of RC220 in combination with doxorubicin in patients with solid tumours

** Approval enables patient enrolment in three clinical trial sites in South Korea

** Approval subject to minor updates in trial protocol

** Stock nearly doubled in value last week after co announced a discovery involving the composition matter of chemotherapy drug Bisantrene

** YTD, stock up 148.9%

 (Reporting by Shruti Agarwal in Bengaluru)

 ((Shruti.Agarwal@thomsonreuters.com))